PEAPACK, N.J. — Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, on Tuesday announced the introduction of Sirolimus to its generic pharmaceutical product line. The product is offered in dosage strengths of 0.5mg x 100.
Greenstone’s Sirolimus product is the authorized generic of, and equivalent to, Pfizer's Rapamune (sirolimus).
Sirolimus is indicated for the prophylaxis of organ rejection in patients ages 13 years or older receiving renal transplants. Therapeutic drug monitoring is recommended for all patients receiving sirolimus.